WAVE.V · Waverley Pharma Inc

-

Please sign in to comment on WAVE.V

1 Comment

Admin

4 years, 3 months ago

Waverley Pharma Inc is currently in a long term downtrend where the price is trading 20.0% below its 200 day moving average.

From a valuation standpoint, the stock is 99.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.4.

Waverley Pharma Inc's total revenue rose by 33.7% to $353K since the same quarter in the previous year.

Its net income has increased by 100.2% to $989 since the same quarter in the previous year.

Finally, its free cash flow grew by 129.3% to $179K since the same quarter in the previous year.

Based on the above factors, Waverley Pharma Inc gets an overall score of 4/5.

CurrencyCode	CAD
Sector	Healthcare
Industry	Biotechnology
Exchange	V
ISIN	CA94357L1058

Beta	2.35
Market Cap	1M
PE Ratio	None
Target Price	10
Dividend Yield	None

ABOUT

Waverley Pharma Inc

Waverley Pharma Inc., a biopharmaceutical company, researches, develops, and commercializes oncology therapeutics in the United Kingdom. The company develops poly ADP-ribose polymerase-1 (PARP-1) inhibitors for cancer treatment. It also operates a retail pharmacy in the United States. Waverley Pharma Inc. was founded in 2014 and is headquartered in Winnipeg, Canada.

WAVE.V · Waverley Pharma Inc

-

Waverley Pharma Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Waverley Pharma Inc using a moving average strategy